



To the European Patent Office  
**Entry into the European phase (EPO as designated or elected Office)**

European application number	
PCT application number	PCT/IB2005/050228
PCT publication number	WO2005073962
Applicant's or representative's reference	PHNL040092EP2
<b>1. Applicant</b> Particulars of the applicant(s) are contained in the international publication or were recorded by the International Bureau subsequent to the international publication. Changes which have not yet been recorded by the International Bureau are set out here: Address for correspondence	
<input checked="" type="checkbox"/> <input type="checkbox"/>	
<b>2. Representative 1</b> This is the representative who will be listed in the Register of European Patents and to whom notifications will be made Name Registration No Address of place of business	
CHAFFRAIX, Mr Jean 014561.5 Société Civile SPID 156 Bd Haussmann PARIS, 75008 France + 33 1 40 76 80 30 + 33 1 45 61 05 36	
Telephone Fax e-mail Any additional representative(s) is/are listed here: <input type="checkbox"/>	
<b>3. General Authorisation:</b> An individual authorisation is attached. <input type="checkbox"/> A general authorisation has been registered under No: <input type="checkbox"/> A general authorisation has been filed, but not yet registered. <input type="checkbox"/> The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase. <input type="checkbox"/>	
<b>4. Request for examination</b> Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid. <input checked="" type="checkbox"/> Request for examination in an admissible non-EPO language: <input checked="" type="checkbox"/> Verzocht wordt om onderzoek van de aanvraag als bedoeld in Art. 94.	
<b>5. Copies</b> One or more additional sets of copies of the documents cited in the supplementary European search report are hereby requested. Number of additional sets of copies <input type="checkbox"/>	
<b>6. Documents intended for proceedings before the EPO</b> <b>6.1</b> Proceedings before the EPO as designated Office (PCT I) are to be based on the following documents: the application documents published by the International Bureau (with all claims, description and drawings), where applicable with amended claims under <input checked="" type="checkbox"/>	

<p><b>Art. 19 PCT</b></p> <p>unless replaced by the amendments attached.</p> <p>Where necessary, clarifications should be attached as 'Other Documents'</p> <p><b>6.2 Proceedings before the EPO as elected Office (PCT II)</b> are to be based on the following documents:</p> <p>the documents on which the international preliminary examination report is based, including any annexes</p> <p>unless replaced by the amendments attached.</p> <p>Where necessary, clarifications should be attached as 'Other Documents'</p> <p>If the EPO as International Preliminary Examining Authority has been supplied with test reports, these may be used as the basis of proceedings before the EPO.</p>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<p><b>7. Translations</b></p> <p>Translations in one of the official languages of the EPO (English, French, German) are attached as crossed below:</p> <ul style="list-style-type: none"> <li>* In proceedings before the EPO as designated or elected Office (PCT I + II):           <ul style="list-style-type: none"> <li>Translation of the international application (description, claims, any text in the drawings) as originally filed, of the abstract as published and of any indication under Rule 13bis.3 and 13bis.4 PCT regarding biological material</li> <li>Translation of the priority application(s)</li> <li>It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC)</li> </ul> </li> <li>* In addition, in proceedings before the EPO as designated Office (PCT I):           <ul style="list-style-type: none"> <li>Translation of amended claims and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6).</li> </ul> </li> <li>* In addition, in proceedings before the EPO as elected office (PCT II):           <ul style="list-style-type: none"> <li>Translation of annexes to the international preliminary examination report</li> </ul> </li> </ul>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<p><b>8. Biological material</b></p> <p>The invention relates to and/or uses biological material deposited under Rule 28 EPC.</p> <p>The particulars referred to in Rule 28(1)(c) EPC (if not yet known, the depositary institution and the identification reference(s)) [number, symbols, etc.] of the depositor) are given in the international publication or in the translation submitted under Section 7 on:</p> <p>page(s) / line(s)</p> <p>A copy of the receipt(s) of deposit issued by the depositary institution is attached</p> <p>will be filed at a later date</p> <p>A waiver of the right to an undertaking from the requester pursuant to Rule 28(3) EPC is attached.</p>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<p><b>9. Nucleotide and amino acid sequences</b></p> <p>The items required under Rules 5.2 and 13ter PCT and Rule 111(3) EPC have already been furnished to the EPO.</p> <p>The sequence listing as part of the description is attached in PDF format.</p> <p>The sequence listing does not include matter that goes beyond the content of the application as filed.</p> <p>In addition, the sequence listing data is attached in computer-readable form in accordance with WIPO Standard 25.</p> <p>The sequence listing data in computer-readable form in accordance with WIPO Standard 25 is identical to the sequence listing in PDF format.</p>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
<p><b>10. Designation fees</b></p> <p>10.1 It is currently intended to pay seven times the amount of the designation fee. The designation fees for all the EPC contracting states designated in the international application are thereby deemed to have been paid (Art. 2 No. 3 RFees).</p>	<input checked="" type="checkbox"/>

AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC  
NL PL PT RO SE SI SK TR

10.2 It is currently intended to pay fewer than seven designation fees for the following EPC contracting states designated in the international application:

10.3 It is requested that no communication under Rules 85a(1) or 69(1) need be notified in respect of the contracting states not indicated. If an automatic debit order has been issued, the EPO is authorised, on expiry of the basic period under Article 79(2), to debit seven times the amount of the designation fee. If less than seven states are indicated, the EPO shall debit designation fees only for those states, unless it is instructed to do otherwise before expiry of the basic period.

#### 11. Extension of the European patent

This application is also considered as being a request for extension to all the non-contracting states to the EPC designated in the international application with which "extension agreements" were in force on the date of filing the international application. However, the extension only takes effect if the prescribed extension fee is paid.

It is currently intended to pay the extension fee for the following states:

#### 12. List of enclosed documents

Description of document	Original file name	Assigned file name
-------------------------	--------------------	--------------------

#### 13. Automatic debit order

Currency

EUR

The European Patent Office is hereby authorised, under the Arrangements for the automatic debiting procedure, to debit from the deposit account any fees and costs falling due.

Deposit account number

28090021

Account holder

PHILIPS INTERNATIONAL B.V. -  
IP&S

#### 14. Reimbursements (if any) should be made to the following EPO deposit account:

Number and account holder

PHILIPS INTERNATIONAL B.V. -  
IP&S, 28090021

#### 15. Fees

		Factor applied	Fee schedule	Amount to be paid
15-1	015 Claims fee	1	40.00	40.00
15-2	020 Basic national fee for an international application	1	90.00	90.00
15-3	033 Renewal fee for the 3rd year	1	380.00	380.00
Total:			EUR	510.00

#### 16. Annotations

#### 17. Signature(s) of applicant(s) or representative

Place:

PARIS

Date:

24.May 2006

Signed by:

FR, Société Civile S.P.I.D., J. Chaffraix  
1193

Capacity:

(Representative)



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

### Acknowledgement of receipt

We hereby acknowledge receipt of the form for entry into the European phase (EPO as designated or elected Office) as follows:

Submission number	123449	
PCT application number	PCT/IB2005/050228	
Date of receipt	24 May 2006	
Receiving Office	European Patent Office, The Hague	
Your reference	PHNL040092EP2	
Applicant		
Country		
Documents submitted	package-data.xml ep-euro-pct.xml	epf1200.pdf (3 p.) application-body.xml
Submitted by	FR, Société Civile S.P.I.D., J. Chaffraix 1193 Subject: FR, Société Civile S.P.I.D., J. Chaffraix 1193; Issuer: European Patent Office, European Patent Office CA	
Method of submission	Online	
Date and time receipt generated	24 May 2006, 16:15:59 (CEST)	
Digest	40:2B:D8:00:EA:A5:FC:51:0D:42:20:F8:D9:65:09:46:07:DF:CF:E4	

/European Patent Office/